芬吗通在重复人工流产术后的临床应用
|
摘要
目的芬吗通在重复人工流产术后的临床应用。方法选择我院2017年8月～2018年8月收治的重复人工流产患者120例,随机分为观察组与对照组各60例,观察组在刮宫术后当天开始口服芬吗通,每天一次,每次一片,坚持服药28天;而对照组术后仅进行常规促进子宫收缩、预防感染治疗。评估两组患者术后阴道流血时间、阴道出血量情况;评估术后14天子宫内膜厚度、月经如期恢复率、宫腔积液、宫腔粘连发生率。结果观察组患者宫腔粘连发生率1例(1.67%)、宫腔积液发生率1例(1.67%)均低于对照组5例(8.33%)、7例(11.67%),(χ~2=4.669、8.032,P <0.05);观察组患者月经如期恢复率59例(98.33%),高于对照组46例(76.67%),(χ~2=21.447,P <0.05)。观察组患者阴道流血时间(4.21±1.00)d短于对照组(6.32±1.02)d,(t=11.442,P <0.05);观察组术后14天子宫内膜厚度(7.26±1.38)mm,高于对照组(4.95±0.85)mm,(t=11.040,P <0.05)。观察组患者阴道出血量多于正常月经量例数所占百分比为12例(20.00%),低于对照组29例(48.33%),(χ~2=17.841,P <0.05);观察组患者阴道出血量少于正常月经量例数所占百分比为38例(63.33%),明显高于对照组20例(33.33%),(χ~2=18.020,P <0.05)。结论对接受重复人工流产术后患者早期应用芬吗通治疗,可有效降低术后并发症风险,缩短阴道出血时间,促进子宫内膜修复。
Objective To analyze the clinical application of Femoston after repeated induced abortion. Methods120 patients with repeated induced abortion who were admitted and treated in our hospital from August 2017 to August 2018 were selected.They were randomly divided into the observation group and the control group,with 60 cases in each group.Patients in the observation group began to take Femoston orally on the day after curettage,one tablet per day for 28 days while patients in the control group were given conventional postoperative treatment to promote uterine contraction and prevent infection.The postoperative vaginal bleeding time and vaginal bleeding volume of patients in two groups were evaluated.Endometrial thickness after 14 days of surgery,recovery rate of menstruation periods,incidence of intrauterine effusion and incidence of intrauterine adhesion were evaluated. Results The incidence of intrauterine adhesion(1 case,1.67%) and intrauterine effusion(1 case,1.67%) in the observation group were both lower than those in the control group(5 cases,8.33%),(7 cases,11.67%),(χ2=4.669,8.032,P < 0.05).The recovery rate of menstruation periods in the observation group(59 cases) was 98.33%,higher than76.67% in the control group(46 cases)(χ2=21.447,P < 0.05).The vaginal bleeding time in the observation group was(4.21±1.00)d,which was shorter than that in the control group [(6.32±1.02)d](t=11.442,P < 0.05).Endometrial thickness after 14 days of surgery in the observation group was(7.26±1.38)mm,higher than that in the control group [(4.95±0.85)mm](t=11.040,P < 0.05).The rate of excessive vaginal bleeding volume in the observation group(12 cases) was 20.00%,lower than 48.33% in the control group(29 cases)(χ2=17.841,P < 0.05).The rate of insufficient vaginal bleeding volume in the observation group(38 cases)was 63.33%,significantly higher than 33.33% in the control group(20 cases)(χ2=18.020,P < 0.05). Conclusion The early application of Femoston in patients with repeated induced abortion can efficiently reduce the risk of postoperative complications, shorten the vaginal bleeding time and promote the recovery of endometrium.
Objective To analyze the clinical application of Femoston after repeated induced abortion. Methods120 patients with repeated induced abortion who were admitted and treated in our hospital from August 2017 to August 2018 were selected.They were randomly divided into the observation group and the control group,with 60 cases in each group.Patients in the observation group began to take Femoston orally on the day after curettage,one tablet per day for 28 days while patients in the control group were given conventional postoperative treatment to promote uterine contraction and prevent infection.The postoperative vaginal bleeding time and vaginal bleeding volume of patients in two groups were evaluated.Endometrial thickness after 14 days of surgery,recovery rate of menstruation periods,incidence of intrauterine effusion and incidence of intrauterine adhesion were evaluated. Results The incidence of intrauterine adhesion(1 case,1.67%) and intrauterine effusion(1 case,1.67%) in the observation group were both lower than those in the control group(5 cases,8.33%),(7 cases,11.67%),(χ2=4.669,8.032,P < 0.05).The recovery rate of menstruation periods in the observation group(59 cases) was 98.33%,higher than76.67% in the control group(46 cases)(χ2=21.447,P < 0.05).The vaginal bleeding time in the observation group was(4.21±1.00)d,which was shorter than that in the control group [(6.32±1.02)d](t=11.442,P < 0.05).Endometrial thickness after 14 days of surgery in the observation group was(7.26±1.38)mm,higher than that in the control group [(4.95±0.85)mm](t=11.040,P < 0.05).The rate of excessive vaginal bleeding volume in the observation group(12 cases) was 20.00%,lower than 48.33% in the control group(29 cases)(χ2=17.841,P < 0.05).The rate of insufficient vaginal bleeding volume in the observation group(38 cases)was 63.33%,significantly higher than 33.33% in the control group(20 cases)(χ2=18.020,P < 0.05). Conclusion The early application of Femoston in patients with repeated induced abortion can efficiently reduce the risk of postoperative complications, shorten the vaginal bleeding time and promote the recovery of endometrium.
引文
[1]蒋景艳.芬吗通片用于96例疤痕子宫人工流产患者术后的效果观察[J].生殖医学杂志,2015,24(2):151-152.
[2]夏玉娟,任玲,姜智慧,等.高危人工流产术后应用芬吗通预防宫腔粘连的临床观察[J].生殖医学杂志,2015,24(3):191-194.
[3]何燕南,葛静.达英-35和芬吗通在稽留流产术后应用价值的观察[J].中国生化药物杂志,2017,37(9):150-152.
[4]张燕妮,周子球,伍凤群,等.人工周期芬吗通在稽留流产患者中的应用与安全性分析[J].中国医药科学,2018,8(10):105-107.
[5]刘桂娟,焦守凤.芬吗通不同给药方式对改善子宫内膜厚度及妊娠情况临床研究[J].中国性科学,2018,27(1):101-103.
[6]赵秀芬,孙蕾芳,王海静,等.芬吗通在稽留流产刮宫术后应用的临床观察[J].生殖医学杂志,2015,24(3):182-185.
[7]刘昊,孙燕,李廉,等.重复人工流产术后药物预防宫腔粘连的临床研究[J].广西医学,2017,39(1):92-94.
[8]王丽琼,韩东红.多次或短期内重复人工流产术后应用戊酸雌二醇片/雌二醇环丙孕酮片复合包装预防宫腔粘连的临床观察[J].中国医师进修杂志,2015,38(2):137-139.
[9]袁虹,杨家义,刘念,等.人工流产相关高危因素分析[J].检验医学与临床,2016,13(9):1204-1206.
[10]何慧丽,李晓荷,金敏丽,等.妇女重复人工流产状况及影响因素探讨[J].中国卫生产业,2018,15(4):160-162.
[11]孙青.优思明用于人工流产后避孕的临床效果观察[J].中国计划生育学杂志,2016,24(9):638-639.
[12]李宾玲,谢华,张军喜,等.人工流产术后口服屈螺酮炔雌醇的临床效果分析[J].中国计划生育学杂志,2015,23(11):790-792.
[13]Friedler S,Margalioth EJ,Kafka I,et al.Incidence of post-abortion intrauterine adhesions evaluated by hysteroscopy-aprospective study[J].Hum Reprod,1993,8:442-444.
[14]麦颂英.不同人工流产方式选择对重复流产的影响探讨[J].中国医药科学,2016,6(24):104-106.
[15]顾向应.人工流产术中并发症的临床诊治及避孕管理[J].中国计划生育学杂志,2017,25(11):724-730.
[16]黄伟燕,应光红,蒋丽华等.药物流产后加用雌激素的疗效分析[J].浙江创伤外科,2016,21(1):155-157.
[2]夏玉娟,任玲,姜智慧,等.高危人工流产术后应用芬吗通预防宫腔粘连的临床观察[J].生殖医学杂志,2015,24(3):191-194.
[3]何燕南,葛静.达英-35和芬吗通在稽留流产术后应用价值的观察[J].中国生化药物杂志,2017,37(9):150-152.
[4]张燕妮,周子球,伍凤群,等.人工周期芬吗通在稽留流产患者中的应用与安全性分析[J].中国医药科学,2018,8(10):105-107.
[5]刘桂娟,焦守凤.芬吗通不同给药方式对改善子宫内膜厚度及妊娠情况临床研究[J].中国性科学,2018,27(1):101-103.
[6]赵秀芬,孙蕾芳,王海静,等.芬吗通在稽留流产刮宫术后应用的临床观察[J].生殖医学杂志,2015,24(3):182-185.
[7]刘昊,孙燕,李廉,等.重复人工流产术后药物预防宫腔粘连的临床研究[J].广西医学,2017,39(1):92-94.
[8]王丽琼,韩东红.多次或短期内重复人工流产术后应用戊酸雌二醇片/雌二醇环丙孕酮片复合包装预防宫腔粘连的临床观察[J].中国医师进修杂志,2015,38(2):137-139.
[9]袁虹,杨家义,刘念,等.人工流产相关高危因素分析[J].检验医学与临床,2016,13(9):1204-1206.
[10]何慧丽,李晓荷,金敏丽,等.妇女重复人工流产状况及影响因素探讨[J].中国卫生产业,2018,15(4):160-162.
[11]孙青.优思明用于人工流产后避孕的临床效果观察[J].中国计划生育学杂志,2016,24(9):638-639.
[12]李宾玲,谢华,张军喜,等.人工流产术后口服屈螺酮炔雌醇的临床效果分析[J].中国计划生育学杂志,2015,23(11):790-792.
[13]Friedler S,Margalioth EJ,Kafka I,et al.Incidence of post-abortion intrauterine adhesions evaluated by hysteroscopy-aprospective study[J].Hum Reprod,1993,8:442-444.
[14]麦颂英.不同人工流产方式选择对重复流产的影响探讨[J].中国医药科学,2016,6(24):104-106.
[15]顾向应.人工流产术中并发症的临床诊治及避孕管理[J].中国计划生育学杂志,2017,25(11):724-730.
[16]黄伟燕,应光红,蒋丽华等.药物流产后加用雌激素的疗效分析[J].浙江创伤外科,2016,21(1):155-157.